Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2010

01.10.2010 | Epidemiology

Common genetic variation of insulin-like growth factor-binding protein 1 (IGFBP-1), IGFBP-3, and acid labile subunit in relation to serum IGF-I levels and mammographic density

verfasst von: Cornelia W. Taverne, Martijn Verheus, James D. McKay, Rudolf Kaaks, Federico Canzian, Diederick E. Grobbee, Petra H. M. Peeters, Carla H. van Gils

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Mammographic density is strongly related to increased breast cancer risk. Accumulating evidence indicates that a role for the IGF-pathway in mammographic density and breast cancer development. Here, we investigate whether common genetic variation in this pathway influences insulin-like growth factor-I (IGF-I) levels and mammographic density. In 1,916 premenopausal women within the Prospect-EPIC cohort, we examined associations of 14 haplotype tagging SNPs in the ALS, IGFBP1, and IGFBP3 genes with IGF-I circulating levels and mammographic density. In 657 women, who became postmenopausal during follow-up, we investigated how these SNPs were related with the decrease in density over menopause. Linear regression models were used for statistical analysis. None of the ALS or IGFBP3 SNPs were statistically significantly associated with IGF-I levels or mammographic density. The CC genotype for rs1908751 (IGFBP1) was associated with lower levels of IGF-I (110.9 ng/ml) compared to the CT/TT genotypes (115.7 ng/ml) (P = 0.04). Women with the CC genotype also had lower percent density, although not statistically significantly (P = 0.12). Women carrying the AA genotype for rs1995051 (IGFBP1) showed that borderline significantly lower IGF-I levels (P = 0.06) and significantly lower mammographic density (40.3% compared to 43.5% in the GG/GA genotypes; P = 0.05). No relationships were found for any of the SNPs in relation with changes in breast density over menopause. These findings suggest that common genetic variation in the IGFBP1 gene is weakly related to IGF-I levels and mammographic density. Our results do not provide support for such a role of genetic variants in the IGFBP3 and ALS genes.
Literatur
1.
Zurück zum Zitat Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, Paterson AD (2005) Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6:798–808CrossRefPubMed Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, Paterson AD (2005) Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6:798–808CrossRefPubMed
2.
Zurück zum Zitat Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, Fishell E, Khokha R, Boyd NF (2001) Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 10:243–248PubMed Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, Fishell E, Khokha R, Boyd NF (2001) Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 10:243–248PubMed
3.
Zurück zum Zitat McCormack VA, dos SS I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:1159–1169CrossRefPubMed McCormack VA, dos SS I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:1159–1169CrossRefPubMed
4.
Zurück zum Zitat Kleinberg DL (1998) Role of IGF-I in normal mammary development. Breast Cancer Res Treat 47:201–208CrossRefPubMed Kleinberg DL (1998) Role of IGF-I in normal mammary development. Breast Cancer Res Treat 47:201–208CrossRefPubMed
5.
Zurück zum Zitat Lee AV, Yee D (1995) Insulin-like growth factors and breast cancer. Biomed Pharmacother 49:415–421CrossRefPubMed Lee AV, Yee D (1995) Insulin-like growth factors and breast cancer. Biomed Pharmacother 49:415–421CrossRefPubMed
6.
7.
Zurück zum Zitat Boyd NF, Stone J, Martin LJ, Jong R, Fishell E, Yaffe M, Hammond G, Minkin S (2002) The association of breast mitogens with mammographic densities. Br J Cancer 87:876–882CrossRefPubMed Boyd NF, Stone J, Martin LJ, Jong R, Fishell E, Yaffe M, Hammond G, Minkin S (2002) The association of breast mitogens with mammographic densities. Br J Cancer 87:876–882CrossRefPubMed
8.
Zurück zum Zitat Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE (2000) Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 60:3744–3748PubMed Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE (2000) Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 60:3744–3748PubMed
9.
Zurück zum Zitat Diorio C, Pollak M, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Berube S, Morin C, Brisson J (2005) Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14:1065–1073CrossRefPubMed Diorio C, Pollak M, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Berube S, Morin C, Brisson J (2005) Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14:1065–1073CrossRefPubMed
10.
Zurück zum Zitat Maskarinec G, Williams AE, Kaaks R (2003) A cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer 107:991–996CrossRefPubMed Maskarinec G, Williams AE, Kaaks R (2003) A cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer 107:991–996CrossRefPubMed
11.
Zurück zum Zitat dos Santos Silva I, Johnson N, De Stavola B, Torres-Mejia G, Fletcher O, Allen DS, Allen NE, Key TJ, Fentiman IS, Holly JM, Peto J (2006) The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women. Cancer Epidemiol Biomarkers Prev 15:449–455CrossRefPubMed dos Santos Silva I, Johnson N, De Stavola B, Torres-Mejia G, Fletcher O, Allen DS, Allen NE, Key TJ, Fentiman IS, Holly JM, Peto J (2006) The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women. Cancer Epidemiol Biomarkers Prev 15:449–455CrossRefPubMed
12.
Zurück zum Zitat Lai JH, Vesprini D, Zhang W, Yaffe MJ, Pollak M, Narod SA (2004) A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol Biomarkers Prev 13:573–582PubMed Lai JH, Vesprini D, Zhang W, Yaffe MJ, Pollak M, Narod SA (2004) A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol Biomarkers Prev 13:573–582PubMed
13.
Zurück zum Zitat Verheus M, Peeters PH, Kaaks R, Van Noord PA, Grobbee DE, Van Gils CH (2007) Premenopausal insulin-like growth factor-I serum levels and changes in breast density over menopause. Cancer Epidemiol Biomarkers Prev 16:451–457CrossRefPubMed Verheus M, Peeters PH, Kaaks R, Van Noord PA, Grobbee DE, Van Gils CH (2007) Premenopausal insulin-like growth factor-I serum levels and changes in breast density over menopause. Cancer Epidemiol Biomarkers Prev 16:451–457CrossRefPubMed
14.
Zurück zum Zitat Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3–34PubMed Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3–34PubMed
15.
Zurück zum Zitat Baxter RC (1994) Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 42:140–144CrossRefPubMed Baxter RC (1994) Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 42:140–144CrossRefPubMed
16.
Zurück zum Zitat Rajah R, Valentinis B, Cohen P (1997) Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272:12181–12188CrossRefPubMed Rajah R, Valentinis B, Cohen P (1997) Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272:12181–12188CrossRefPubMed
17.
Zurück zum Zitat Schedlich LJ, Graham LD (2002) Role of insulin-like growth factor binding protein-3 in breast cancer cell growth. Microsc Res Tech 59:12–22CrossRefPubMed Schedlich LJ, Graham LD (2002) Role of insulin-like growth factor binding protein-3 in breast cancer cell growth. Microsc Res Tech 59:12–22CrossRefPubMed
18.
Zurück zum Zitat Al Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA, Luccarini C, Munday H, Perkins B, Smith P, Pharoah PD, Wareham NJ, Easton DF, Ponder BA, Dunning AM (2006) IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 15:1–10CrossRefPubMed Al Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA, Luccarini C, Munday H, Perkins B, Smith P, Pharoah PD, Wareham NJ, Easton DF, Ponder BA, Dunning AM (2006) IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 15:1–10CrossRefPubMed
19.
Zurück zum Zitat Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S, Landi S, Boillot C, Monnier S, Chajes V, Clavel-Chapelon F, Tehard B, Chang-Claude J, Linseisen J, Lahmann PH, Pischon T, Trichopoulos D, Trichopoulou A, Zilis D, Palli D, Tumino R, Vineis P, Berrino F, Bueno-de-Mesquita HB, Van Gils CH, Peeters PH, Pera G, Ardanaz E, Chirlaque MD, Quiros JR, Larranaga N, Martinez-Garcia C, Allen NE, Key TJ, Bingham SA, Khaw KT, Slimani N, Norat T, Riboli E, Kaaks R (2006) Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 94:299–307CrossRefPubMed Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S, Landi S, Boillot C, Monnier S, Chajes V, Clavel-Chapelon F, Tehard B, Chang-Claude J, Linseisen J, Lahmann PH, Pischon T, Trichopoulos D, Trichopoulou A, Zilis D, Palli D, Tumino R, Vineis P, Berrino F, Bueno-de-Mesquita HB, Van Gils CH, Peeters PH, Pera G, Ardanaz E, Chirlaque MD, Quiros JR, Larranaga N, Martinez-Garcia C, Allen NE, Key TJ, Bingham SA, Khaw KT, Slimani N, Norat T, Riboli E, Kaaks R (2006) Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 94:299–307CrossRefPubMed
20.
Zurück zum Zitat Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, Pollak M (2001) Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86:1274–1280CrossRefPubMed Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, Pollak M (2001) Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86:1274–1280CrossRefPubMed
21.
Zurück zum Zitat Ren Z, Cai Q, Shu XO, Cai H, Li C, Yu H, Gao YT, Zheng W (2004) Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev 13:1290–1295PubMed Ren Z, Cai Q, Shu XO, Cai H, Li C, Yu H, Gao YT, Zheng W (2004) Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev 13:1290–1295PubMed
22.
Zurück zum Zitat Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN (2003) Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 107:60–64CrossRefPubMed Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN (2003) Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 107:60–64CrossRefPubMed
23.
Zurück zum Zitat Tamimi RM, Cox DG, Kraft P, Pollak MN, Haiman CA, Cheng I, Freedman ML, Hankinson SE, Hunter DJ, Colditz GA (2007) Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res 9:R18CrossRefPubMed Tamimi RM, Cox DG, Kraft P, Pollak MN, Haiman CA, Cheng I, Freedman ML, Hankinson SE, Hunter DJ, Colditz GA (2007) Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res 9:R18CrossRefPubMed
24.
Zurück zum Zitat Riboli E, Kaaks R (1997) The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 26(Suppl 1):S6–S14CrossRefPubMed Riboli E, Kaaks R (1997) The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 26(Suppl 1):S6–S14CrossRefPubMed
25.
Zurück zum Zitat Boker LK, Van Noord PA, van der Schouw YT, Koot NV, Bueno De Mesquita HB, Riboli E, Grobbee DE, Peeters PH (2001) Prospect-EPIC Utrecht: study design and characteristics of the cohort population. European Prospective Investigation into Cancer and Nutrition. Eur J Epidemiol 17:1047–1053CrossRefPubMed Boker LK, Van Noord PA, van der Schouw YT, Koot NV, Bueno De Mesquita HB, Riboli E, Grobbee DE, Peeters PH (2001) Prospect-EPIC Utrecht: study design and characteristics of the cohort population. European Prospective Investigation into Cancer and Nutrition. Eur J Epidemiol 17:1047–1053CrossRefPubMed
26.
Zurück zum Zitat Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ et al (2005) A haplotype map of the human genome. Nature 437:1299–1320CrossRef Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ et al (2005) A haplotype map of the human genome. Nature 437:1299–1320CrossRef
27.
Zurück zum Zitat Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265CrossRefPubMed Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265CrossRefPubMed
28.
Zurück zum Zitat Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ (1994) The quantitative analysis of mammographic densities. Phys Med Biol 39:1629–1638CrossRefPubMed Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ (1994) The quantitative analysis of mammographic densities. Phys Med Biol 39:1629–1638CrossRefPubMed
29.
Zurück zum Zitat Boyd NF, Martin LJ, Sun L, Guo H, Chiarelli A, Hislop G, Yaffe M, Minkin S (2006) Body size, mammographic density, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 15:2086–2092CrossRefPubMed Boyd NF, Martin LJ, Sun L, Guo H, Chiarelli A, Hislop G, Yaffe M, Minkin S (2006) Body size, mammographic density, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 15:2086–2092CrossRefPubMed
30.
Zurück zum Zitat Renehan AG, Frystyk J, Flyvbjerg A (2006) Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 17:328–336CrossRefPubMed Renehan AG, Frystyk J, Flyvbjerg A (2006) Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 17:328–336CrossRefPubMed
31.
Zurück zum Zitat Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434–442CrossRefPubMed Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434–442CrossRefPubMed
32.
Zurück zum Zitat Patel AV, Cheng I, Canzian F, Le ML, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorronsoro M, Dossus L, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Linseisen J, Lund E, Manjer J, McCarty C, Peeters PH, Pike MC, Pollak M, Riboli E, Stram DO, Tjonneland A, Travis RC, Trichopoulos D, Tumino R, Yeager M, Ziegler RG, Feigelson HS (2008) IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE 3:e2578CrossRefPubMed Patel AV, Cheng I, Canzian F, Le ML, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorronsoro M, Dossus L, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Linseisen J, Lund E, Manjer J, McCarty C, Peeters PH, Pike MC, Pollak M, Riboli E, Stram DO, Tjonneland A, Travis RC, Trichopoulos D, Tumino R, Yeager M, Ziegler RG, Feigelson HS (2008) IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE 3:e2578CrossRefPubMed
33.
Zurück zum Zitat Diorio C, Brisson J, Berube S, Pollak M (2008) Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev 17:880–888CrossRefPubMed Diorio C, Brisson J, Berube S, Pollak M (2008) Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev 17:880–888CrossRefPubMed
34.
Zurück zum Zitat Boyd N, Martin L, Stone J, Little L, Minkin S, Yaffe M (2002) A longitudinal study of the effects of menopause on mammographic features. Cancer Epidemiol Biomarkers Prev 11:1048–1053PubMed Boyd N, Martin L, Stone J, Little L, Minkin S, Yaffe M (2002) A longitudinal study of the effects of menopause on mammographic features. Cancer Epidemiol Biomarkers Prev 11:1048–1053PubMed
35.
Zurück zum Zitat Maskarinec G, Pagano I, Lurie G, Kolonel LN (2006) A longitudinal investigation of mammographic density: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 15:732–739CrossRefPubMed Maskarinec G, Pagano I, Lurie G, Kolonel LN (2006) A longitudinal investigation of mammographic density: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 15:732–739CrossRefPubMed
36.
Zurück zum Zitat Vachon CM, Pankratz VS, Scott CG, Maloney SD, Ghosh K, Brandt KR, Milanese T, Carston MJ, Sellers TA (2007) Longitudinal trends in mammographic percent density and breast cancer risk. Cancer Epidemiol Biomarkers Prev 16:921–928CrossRefPubMed Vachon CM, Pankratz VS, Scott CG, Maloney SD, Ghosh K, Brandt KR, Milanese T, Carston MJ, Sellers TA (2007) Longitudinal trends in mammographic percent density and breast cancer risk. Cancer Epidemiol Biomarkers Prev 16:921–928CrossRefPubMed
37.
Zurück zum Zitat Kerlikowske K, Ichikawa L, Miglioretti DL, Buist DS, Vacek PM, Smith-Bindman R, Yankaskas B, Carney PA, Ballard-Barbash R (2007) Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst 99:386–395CrossRefPubMed Kerlikowske K, Ichikawa L, Miglioretti DL, Buist DS, Vacek PM, Smith-Bindman R, Yankaskas B, Carney PA, Ballard-Barbash R (2007) Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst 99:386–395CrossRefPubMed
38.
Zurück zum Zitat Twisk JWR (2005) Applied longitudinal data analysis for epidemiology: a practical guide. Cambridge University Press, Cambridge Twisk JWR (2005) Applied longitudinal data analysis for epidemiology: a practical guide. Cambridge University Press, Cambridge
39.
Zurück zum Zitat van Duijnhoven FJ, Peeters PH, Warren RM, Bingham SA, Van Noord PA, Monninkhof EM, Grobbee DE, Van Gils CH (2007) Postmenopausal hormone therapy and changes in mammographic density. J Clin Oncol 25:1323–1328CrossRefPubMed van Duijnhoven FJ, Peeters PH, Warren RM, Bingham SA, Van Noord PA, Monninkhof EM, Grobbee DE, Van Gils CH (2007) Postmenopausal hormone therapy and changes in mammographic density. J Clin Oncol 25:1323–1328CrossRefPubMed
40.
Zurück zum Zitat Allen NE, Appleby PN, Kaaks R, Rinaldi S, Davey GK, Key TJ (2003) Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women. Cancer Causes Control 14:65–74CrossRefPubMed Allen NE, Appleby PN, Kaaks R, Rinaldi S, Davey GK, Key TJ (2003) Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women. Cancer Causes Control 14:65–74CrossRefPubMed
41.
Zurück zum Zitat Holmes MD, Pollak MN, Hankinson SE (2002) Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 11:862–867PubMed Holmes MD, Pollak MN, Hankinson SE (2002) Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 11:862–867PubMed
42.
Zurück zum Zitat Voskuil DW, Bueno De Mesquita HB, Kaaks R, Van Noord PA, Rinaldi S, Riboli E, Grobbee DE, Peeters PH (2001) Determinants of circulating insulin-like growth factor (IGF)-I and IGF binding proteins 1–3 in premenopausal women: physical activity and anthropometry (Netherlands). Cancer Causes Control 12:951–958CrossRefPubMed Voskuil DW, Bueno De Mesquita HB, Kaaks R, Van Noord PA, Rinaldi S, Riboli E, Grobbee DE, Peeters PH (2001) Determinants of circulating insulin-like growth factor (IGF)-I and IGF binding proteins 1–3 in premenopausal women: physical activity and anthropometry (Netherlands). Cancer Causes Control 12:951–958CrossRefPubMed
43.
Zurück zum Zitat Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S, Dossus L, Micheli A, Arslan A, Lenner P, Shore RE, Krogh V, Koenig KL, Riboli E, Berrino F, Hallmans G, Stattin P, Toniolo P, Kaaks R (2004) Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 150:161–171CrossRefPubMed Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S, Dossus L, Micheli A, Arslan A, Lenner P, Shore RE, Krogh V, Koenig KL, Riboli E, Berrino F, Hallmans G, Stattin P, Toniolo P, Kaaks R (2004) Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 150:161–171CrossRefPubMed
44.
Zurück zum Zitat Baxter RC (2001) Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 54:145–148CrossRefPubMed Baxter RC (2001) Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 54:145–148CrossRefPubMed
Metadaten
Titel
Common genetic variation of insulin-like growth factor-binding protein 1 (IGFBP-1), IGFBP-3, and acid labile subunit in relation to serum IGF-I levels and mammographic density
verfasst von
Cornelia W. Taverne
Martijn Verheus
James D. McKay
Rudolf Kaaks
Federico Canzian
Diederick E. Grobbee
Petra H. M. Peeters
Carla H. van Gils
Publikationsdatum
01.10.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-0778-2

Weitere Artikel der Ausgabe 3/2010

Breast Cancer Research and Treatment 3/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.